Vakharia insights from the ARCHER trial on geographic atrophy treatment for dry AMD, highlighting promising results and ...

The Food and Drug Administration (FDA) has approved Susvimo ® (ranibizumab injection) for the treatment of patients with ...

In a moment that drew applause and admiration from Ghana’s top business and political leaders, Dr. Michael Ekuoba Gyasi, Executive Director of St. Thomas ...

In this video, Jay Chhablani, MD, discusses findings from the LIGHTSITE 3B study presented at the ARVO meeting on the long-term use of photobiomodulation in dry age-related macular degeneration.

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...

What is the difference between prediabetes and diabetes, and which do I have? I am male, 85 years old, 170 pounds, and 6 feet ...

discusses findings from the LIGHTSITE 3B study presented at the ARVO meeting on the long-term use of photobiomodulation in dry age-related macular degeneration. The FDA granted rare pediatric ...

Macular degeneration is a prevalent eye disorder that typically results in loss of vision in individuals who are 50 years of age and older. Although there isn’t a recognized cure for this ...

Based on the scientific progress achieved in the past few years, it is possible that patients with myopic macular degeneration complicated by CNV may benefit from a new ophthalmic frontier of ...

This is also called age-related macular degeneration (AMD), as the major risk factor for this is aging. It is an eye disorder characterized by a number of conditions negatively affecting the macula.

Neurodegenerative diseases are a heterogeneous group of disorders that are characterized by the progressive degeneration of the structure and function of the central nervous system or peripheral ...